Obesity currently affects more than one billion people worldwide and is classified by the World Health Organization as a chronic, multifactorial disease defined by the excessive accumulation of adipose tissue. Its consequences reach far beyond body weight, extending into type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease and several cancers. The global economic burden is projected to reach trillions of US dollars annually by 2035. Yet existing treatments remain imperfect. Lifestyle interventions suffer from poor long-term adherence and frequent weight regain; pharmacological options such as GLP-1 receptor agonists and orlistat carry side effects ranging from gastrointestinal distress to cardiovascular risks, along with substantial costs; and bariatric surgery, while effective, is invasive and accessible to only a small fraction of those who need it. This treatment gap has driven growing scientific interest in food-derived bioactives as safer, more accessible complements or alternatives.

Rhizomes—the underground stems of plants such as turmeric (Curcuma longa), ginger (Zingiber officinale) and kencur (Kaempferia galanga)—are dense repositories of polyphenols, flavonoids and essential oils. However, many of their most celebrated compounds, including curcumin, suffer from notoriously poor water solubility, rapid systemic clearance and low oral bioavailability, which sharply constrain their therapeutic efficacy in conventional preparations. Fermentation offers a bioprocessing solution. When microorganisms such as lactic acid bacteria or filamentous fungi colonize the starch- and fibre-rich rhizome matrix, their enzymes cleave glycosidic and ester linkages, deconjugate polyphenols and generate structurally novel metabolites that simply do not exist in the raw plant. In one striking example documented in the review, fermentation of wild turmeric (Curcuma aromatica) with the fungus Rhizopus oligosporus produced l-carnitine de novo—a compound essential for transporting fatty acids into mitochondria for fat burning—reaching concentrations of up to 242 micrograms per gram, despite being absent from the unfermented substrate.

The metabolic by-products of this microbial transformation fall under the heading of postbiotics, a term defined by the International Scientific Association for Probiotics and Prebiotics as preparations of inanimate microorganisms and their components that confer a health benefit. Unlike probiotics, postbiotics do not require viable microorganisms, offering advantages in shelf stability, safety and standardization. Key postbiotic constituents generated during rhizome fermentation include short-chain fatty acids, bacteriocins, exopolysaccharides, bioactive peptides and biotransformed polyphenolic metabolites. The review’s authors are careful to note a nomenclature issue: because most included studies did not confirm microbial inactivation before administering their preparations, the team distinguishes throughout between “fermented rhizome products” as whole matrices and postbiotics in the strict sense, reserving the latter term for the specific bioactive metabolites hypothesized to mediate the observed effects.

To build this mechanistic framework, the researchers conducted the review under PRISMA guidelines, prospectively registering the protocol in PROSPERO. They searched four major databases—PubMed, Scopus, Web of Science and Embase—covering all records through April 2026, and screened 1307 initial records down to ten studies that met rigorous inclusion criteria. These comprised eight in vivo animal studies and two in vitro cell-culture studies spanning five rhizome species, with turmeric the most frequently investigated. Fermentation organisms were dominated by lactic acid bacteria, particularly Lactobacillus plantarum and L. paracasei, alongside filamentous fungi including Aspergillus oryzae, Eurotium cristatum and Rhizopus oligosporus. Animal models ranged from high-fat-diet-induced obesity in C57BL/6 mice and Sprague-Dawley rats to genetic obesity in ob/ob mice and spontaneous obesity in OLETF rats. Risk of bias was assessed using SYRCLE’s tool for animal studies and the ToxRTool for in vitro work, with both cell-culture studies achieving the highest reliability category.

Perhaps the most compelling evidence came from the six studies that directly compared fermented against unfermented preparations. In every single head-to-head comparison, the fermented product outperformed its unfermented counterpart on at least one assessed outcome. Fermented Rhizoma Atractylodis Macrocephalae more effectively reduced adipose tissue weight and improved serum triglycerides than the raw rhizome. Fermented turmeric suppressed weight gain and modulated gut microbiota more powerfully than unfermented turmeric—even though fermentation had actually reduced its curcuminoid content, a paradox suggesting that benefits may flow from biotransformed compounds, enhanced bioavailability or fermentation-derived metabolites rather than the parent phytochemicals alone. Fermented Panax notoginseng uniquely suppressed food intake and produced stronger weight reduction than the raw preparation, while fermented Polygonatum polysaccharides showed superior inhibition of adipogenesis in vitro.

The gut microbiota emerged as a central mediator of these effects. Across four in vivo studies that profiled host gut bacteria, fermented rhizome treatment consistently improved the ratio of Bacteroidetes to Firmicutes—a microbial signature repeatedly disrupted in obesity—and restored alpha diversity toward levels seen in normal-diet controls. Particularly striking was the enrichment of Akkermansia muciniphila, a mucus-degrading bacterium strongly associated with improved metabolic health and reduced gut permeability, which appeared in three independent studies using taxonomically distinct rhizome species. Fermented turmeric treatment also elevated faecal acetic, propionic and butyric acids—short-chain fatty acids that act through G-protein-coupled receptors to regulate lipid oxidation, insulin secretion and energy expenditure. Butyrate in particular was linked to the activation of thermogenic pathways in brown adipose tissue through upregulation of the metabolic enzymes ACSM3 and HADH, providing a direct microbiota-to-calorie-burning communication axis.

At the molecular level, the review identified at least six mechanistic axes of action. Suppression of adipogenesis—the process by which precursor cells mature into fat-storing adipocytes—was the most broadly shared, with multiple studies reporting downregulation of the master transcription factors PPAR-γ and C/EBPα and their downstream lipogenic enzymes. Conversely, lipolysis was enhanced through upregulation of HSL and ATGL and activation of PKA signalling. AMP-activated protein kinase, or AMPK, served as a central convergence node; in the most mechanistically complete study, fermented turmeric activated the AMPK–SIRT1–PGC-1α signalling triad, restoring mitochondrial oxidative capacity and energy expenditure while simultaneously suppressing endoplasmic reticulum stress and Nox4-mediated oxidative damage. Additional axes included improved insulin signalling via the PI3K/Akt pathway, attenuation of inflammatory cytokines including TNF-α, IL-6 and IL-1β, restoration of intestinal barrier integrity with reduced circulating endotoxin, and modulation of hypothalamic appetite regulation.

The metabolic results across the animal studies were substantive. All eight in vivo studies reported reductions in body weight gain or adipose tissue mass, and lipid profiles improved consistently, with reductions in serum and hepatic triglycerides in seven studies and HDL-cholesterol increases in four. One dose-response study documented that fermented turmeric extract at 200 and 500 milligrams per kilogram reduced weight gain by 12 and 22 percent respectively, while raising HDL-cholesterol by 53 to 67 percent. Glucose metabolism improved in the four studies assessing it, with reductions in fasting glucose, insulin and HOMA-IR, and thermogenic markers such as UCP-1 and adiponectin rose across several investigations.

The authors temper their enthusiasm with appropriate scientific caution. Using the OHAT framework, they rated the certainty of evidence as low or very low across all mechanistic axes, reflecting an entirely preclinical evidence base with predominantly unclear-to-high risk of bias in areas such as randomization and blinding. Substantial heterogeneity—five rhizome species, seven fermentation organisms, three product forms and multiple obesity models—prevented even a restricted quantitative meta-analysis. No human clinical data exist for these preparations. Nevertheless, the mechanistic coherence and cross-species consistency of the findings provide a preliminary foundation for the development of rhizome-based functional foods. The research team calls for randomized human intervention trials with standardized preparations, germ-free animal models to formally establish causal microbiota mechanisms, and bioactivity-guided fractionation to attribute specific effects to defined postbiotic compounds. If those trials succeed, the humble fermenting vat—humanity’s oldest food technology—may yet yield a new generation of evidence-based dietary tools against obesity.